Welcome to BioSeeker Group!

Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking

Additional Information

Published Date Apr 3, 2009
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 522
PDF Fact Sheet View Fact Sheet for the report Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio of leukemia products.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking.

    To find out more about Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report includes defined and up to date development strategies for 175 leukemia drugs (>250 projects) within the portfolio of 126 investigators, from Preclinical to Marketed. Leukemia drugs are further dived into the sub-indications of ALL, AML, CLL, CML, HCL and MCL. The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:

  • Providing competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing commercial analytic support for due diligence on in-licensing and acquisition opportunities

This report will also be an important part of creating and implementing a market development plan for any leukemia drugs to ensure that the optimal market conditions exist by the time the product is commercialized.

BioSeeker’s leukemia pipeline evaluation of development options, competitive landscape and positioning is derived through extensive pipeline benchmarking analysis, including:

Single Drug Target Analysis of 136 Drug Targets

  • Highlighting twelve themes about the drug target (i.e. Drugs and investigators sharing a particular target, Types of compounds aimed at a specific target, Protein-protein interactions of a specific target with other known leukemia drug targets, Pathway involvement of a drug target, Presence of structural and protein expression data of a target etc.)
  • Supportive chapters on selected drug themes above

Competitive Landscape Analysis based on 115 Identified Drug Target Combinations

  • Identifies New and Unique leukemia drugs by developmental stage
  • Head-to-head targeting competition
  • Targeting competition by at least 50% bi-directional drug target combination match
  • Clinical validation and progress on all identified drug target combinations

Competitive Landscape Analysis based on Compound Strategies at Work

  • Identifies New and Unique leukemia drugs based on six different compound strategies (Small molecules, Peptide/Protein, Antibody, Nucleic acid therapies, Gene therapy and Re-formulation drugs)
  • Head-to-head targeting competition
  • Targeting competition by at least 50% bi-directional drug target combination match

Competitive Benchmarking of Leukemia Pipeline by 126 Investigators

  • Competitive Fall-out table for each of the included investigators’ leukemia pipeline, overlaid with head-to-head targeting competitors’ drugs
  • Competitive summary profile for each one of the 175 included leukemia drugs

1 Executive Summary 3
2 About Cancer Highlights 5
3 Methodologies 7
4 Table of Contents 9
4.1 List of Figures 17
4.2 List of Tables 17
5 Introduction 22
6 Single Drug Target Benchmarking from the Leukemia Pipeline 25
6.1.1 Carboxy-Lyase Activity Targets 26
6.1.2 Catalytic Activity Targets 27
6.1.3 Cell Adhesion Molecule Activity Targets 33
6.1.4 Chaperone Activity Targets 34
6.1.5 Cysteine-Type Peptidase Activity Targets 36
6.1.6 Cytokine Activity Targets 39
6.1.7 Deaminase Activity Targets 41
6.1.8 DNA Repair Protein Targets 42
6.1.9 DNA Topoisomerase Activity Targets 43
6.1.10 DNA-Directed DNA Polymerase Activity Targets 45
6.1.11 DNA-Methyltransferase Activity Targets 51
6.1.12 G-Protein Coupled Receptor Activity Targets 52
6.1.13 Growth Factor Activity Targets 53
6.1.14 Hydrolase Activity Targets 55
6.1.15 Kinase Activity Targets 57
6.1.16 Kinase Regulator Activity Targets 64
6.1.17 Ligand-Dependent Nuclear Receptor Activity Targets 65
6.1.18 Ligase Activity Targets 66
6.1.19 Lipid Kinase Activity Targets 67
6.1.20 MHC Class I Receptor Activity Targets 68
6.1.21 Molecular Function Unknown Targets 69
6.1.22 Motor Activity Targets 73
6.1.23 Oxidoreductase activity Targets 74
6.1.24 Phosphoric diester hydrolase activity Targets 77
6.1.25 Phosphorylase activity Targets 81
6.1.26 Protein Binding Targets 84
6.1.27 Protein serine/threonine kinase activity Targets 85
7.1.2 Protein tyrosine phosphatase activity Targets 109
7.1.3 Protein-tyrosine kinase activity Targets 115
7.1.4 Receptor Activity Targets 130
7.1.5 Receptor Signaling Complex Scaffold Activity Targets 142
7.1.6 RNA Binding Targets 147
7.1.7 RNA-Directed DNA Polymerase Activity Targets 148
7.1.8 Serine-Type Peptidase Activity Targets 149
7.1.9 Structural Constituent Of Cytoskeleton Targets 151
7.1.10 Superoxide dismutase activity Targets 152
7.1.11 T Cell Receptor Activity Targets 154
7.1.12 Transcription Factor Activity Targets 156
7.1.13 Transcription Regulator Activity Targets 163
7.1.14 Transferase Activity Targets 169
7.1.15 Translation Regulator Activity Targets 170
7.1.16 Transmembrane receptor activity Targets 172
7.1.17 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 176
7.1.18 Transporter activity Targets 203
7.1.19 Other Targets 207
7.2 The Cancer Genome Project and Leukemia Targets 208
7.2.1 Leukemia Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 208
7.3 Structure-based Drug Design in Leukemia is Stimulated by Available Structure Data on Biological Targets 211
7.4 Target-Target Interactions among Identified Leukemia Targets 215
7.5 The Drug-Target Interactome 219
7.6 Protein Expression Levels of Identified Drug Targets of Leukemia Drugs 224
7.7 Pathway Analysis of Leukemia Drug Targets 227
8 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Combinations Identified in the Leukemia Pipeline? 266
8.1 Pre-Registration to being Marketed: New and Unique Drug Target Combinations of the Leukemia Pipeline 269
8.2 Phase III Clinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline 271
8.3 Phase II Clinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline 272
8.4 Phase I Clinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline 275
8.5 Preclinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline 277
8.6 Development Profiles of All Leukemia Drug Target Combinations 278
9 Compound Strategies at Work: Competitive Benchmarking of Leukemia Pipeline by Type of Compound 294
9.1 Small Molecules 296
9.1.1 Background 296
9.1.2 Targets in Leukemia 297
9.2 Peptide/Protein Drugs 306
9.2.1 Background 306
9.2.2 Targets in Leukemia 307
9.3 Antibodies and Antibody-like Structures 310
9.3.1 Background 310
9.3.2 Targets in Leukemia 310
9.4 Nucleic Acid Therapies 313
9.4.1 Background 313
9.4.2 Targets in Leukemia 314
9.5 Gene Therapy 315
9.5.1 Background 315
9.5.2 Targets in Leukemia 315
9.6 Drug Delivery and Nanotechnology 317
9.6.1 Background 317
9.6.2 Targets in Leukemia 317
9.7 Compound Strategies based on Sub-Cellular Localization of Leukemia Drug Targets 319
10 Portfolio Planning: Competitive Benchmarking of Leukemia Pipeline by Investigator 325
10.1 4SC 327
10.2 Abbott 328
10.3 Abiogen 330
10.4 Actinium Pharmaceuticals 331
10.5 AEgera 332
10.6 Aeterna Zentaris 334
10.7 Agennix 336
10.8 Alexion 337
10.9 Alfa Wassermann 338
10.10 Ambit Biosciences 340
10.11 Amgen 342
10.12 Antigenics 343
10.13 Antisoma 345
10.14 Ariad 347
10.15 Arno Therapeutics 349
10.16 Array BioPharma 350
10.17 Asahi Kasei Pharma 351
10.18 Ascenta Therapeutics 352
10.19 Astellas 353
10.20 Astex Therapeutics 354
10.21 AstraZeneca 356
10.22 Attenuon 357
10.23 Bayer 358
10.24 BioCryst Pharmaceuticals 360
10.25 Biogen Idec 361
10.26 Bioton 364
10.27 Boehringer Ingelheim 366
10.28 Bristol-Myers Squibb 368
10.29 BTG 370
10.30 Calistoga Pharmaceuticals 372
10.31 Callisto Pharmaceuticals 373
10.32 Celator Pharmaceuticals 375
10.33 Cell Genesys 376
10.34 Cell Therapeutics 377
10.35 Cephalon 379
10.36 CJ Corp 380
10.37 Clavis Pharma 382
10.38 Curacyte 383
10.39 Cyclacel 384
10.40 Cylene Pharmaceuticals 385
10.41 CytImmune Sciences 386
10.42 Cytokinetics 387
10.43 Daiichi Sankyo 388
10.44 Dainippon Sumitomo Pharma 389
10.45 Dara Biosciences 390
10.46 Deciphera Pharmaceuticals 391
10.47 Dong-A 393
10.48 Eleos 395
10.49 Eli Lilly 396
10.50 Enzon 398
10.51 EpiCept 400
10.52 Exelixis 401
10.53 ExonHit Therapeutics 403
10.54 Gemin X Pharmaceuticals 404
10.55 Genentech 405
10.56 Genmab 408
10.57 Genta 410
10.58 Genzyme 412
10.59 Geron 414
10.60 GlaxoSmithKline 416
10.61 Gloucester Pharmaceuticals 418
10.62 GlycoGenesys 419
10.63 Hayashibara 420
10.64 Hoffmann-La Roche 422
10.65 ImClone Systems 424
10.66 Immunomedics 425
10.67 Innate Pharma 427
10.68 Innovive 428
10.69 Isis Pharmaceuticals 429
10.70 Italfarmaco 430
10.71 Johnson & Johnson 431
10.72 Kanisa 432
10.73 Kyowa Hakko Kirin 433
10.74 LG Life Sciences 434
10.75 Lorus Therapeutics 437
10.76 MAT Biopharma 438
10.77 MaxCyte 439
10.78 Meda 440
10.79 Medarex 442
10.80 MethylGene 444
10.81 Micromet 445
10.82 MorphoSys 447
10.83 NanoMed Pharmaceuticals 448
10.84 Nerviano Medical Sciences 449
10.85 National Institute of Health (USA) 450
10.86 Nippon Shinyaku 452
10.87 Novartis 454
10.88 Novogen 459
10.89 PDL BioPharma 460
10.90 Peplin 462
10.91 Pfizer 463
10.92 Pharmacyclics 466
10.93 PharmaMar 467
10.94 PIERIS Proteolab 468
10.95 Rigel 469
10.96 Sanofi-Aventis 470
10.97 Santaris Pharma 471
10.98 SBIO 472
10.99 Schering-Plough 473
10.100 SciGen 474
10.101 Seattle Genetics 476
10.102 Sepal Pharma 477
10.103 Servier 478
10.104 Shantha Biotechnics 480
10.105 Sidus 482
10.106 Spirogen 484
10.107 Stemline Therapeutics 485
10.108 SuperGen 486
10.109 Supratek Pharma 488
10.110 Swedish Orphan 490
10.111 SymBio Pharmaceuticals 492
10.112 Takeda 493
10.113 Teva 495
10.114 TopoTarget 496
10.115 Trion Pharma 498
10.116 Trubion 499
10.117 Vertex Pharmaceuticals 500
10.118 Vion Pharmaceuticals 501
10.119 VioQuest 503
10.120 Wyeth 505
10.121 Yamasa Corporation 507
10.122 Zenyaku Kogyo 509
10.123 ZymoGenetics 511
10.124 Non-Industrial Sources 512
11 Disclaimer 514
12 Drug Index 515
13 Company Index 519

4.1 List of Figures
Figure 1: Overall Breakdown of Included Leukemia Pipeline by Sub-indication and Stage of Development 23
Figure 2: Visualization of Target-Target Interactions Among Leukemia Drug Targets 218
Figure 3: The Drug-Protein Interactome of Leukemia Drugs – The Main Cluster 221
Figure 4: The Drug-Protein Interactome of Leukemia Drugs – Smaller Clusters 222
Figure 5: Head-to-Head Targeting Interactome of Leukemia Drugs 223
Figure 6: Distribution of Compound Types among Leukemia Drugs 319
Figure 7: Primary Sub-cellular Localization of Drug Targets 320

4.2 List of Tables
Table 1: Overview of Drug Target Profile Themes 25
Table 2: Drug Targets of Leukemia Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 209
Table 3: Identity of Leukemia Drug Targets with Available Biological Structures 212
Table 4: Number of Target-Target Interactions among Leukemia Drug Targets 215
Table 5: Drug-Protein Interactome Clusters 219
Table 6: Leukemia Drug Targets with Available Protein Expression Profiles 224
Table 7: Pathway Summary 227
Table 8: Drug Targets without any Identified Assigned Pathways 227
Table 9: Pathway Profile According to BioCarta of Leukemia Drug Targets 228
Table 10: Pathway Profile According to KEGG of Leukemia Drug Targets 244
Table 11: Pathway Profile According to NetPath of Leukemia Drug Targets 261
Table 12: Number of Drug Target Combinations by the Highest Developmental Stage and Uniqueness 266
Table 13: Top 5 Competitive Leukemia Targets 267
Table 14 New and Unique Leukemia Targets in Pre-Registration to Marketed 269
Table 15: New and Unique Leukemia Targets in Phase III Clinical Development 271
Table 16: New and Unique Leukemia Targets in Phase II Clinical Development 273
Table 17 New and Unique Leukemia Targets in Phase I Clinical Development 275
Table 18: New and Unique Leukemia Targets in Preclinical Development 277
Table 19: The Progression, Maturity and Competitive Comparison of Leukemia Drug Target Combinations in Development 278
Table 20: Number of Leukemia Drug Target Mixes Reported by Compound Strategy 295
Table 21: Number of Head-to-head Competing Small Molecule Drugs for the Treatment of Leukemia by Drug Target 297
Table 22: Drug Targets of Small Molecule Drugs in Leukemia 298
Table 23: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs in Leukemia 304
Table 24: Drug Targets of Peptide Based Drugs in Leukemia 307
Table 25: Drug Targets of Protein Based Drugs in Leukemia 308
Table 26: Drug Targets of Antibodies and Antibody-like Drugs in Leukemia 310
Table 27: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Leukemia 312
Table 28: Drug Targets of Nucleic Acid Therapies in Leukemia 314
Table 29: Vectors in Gene Therapy 315
Table 30: Drug Targets of Gene Therapies in Leukemia 316
Table 31: Drug Targets with New Drug Delivery Strategies in Leukemia 318
Table 32: Compound Strategies based on Sub-Cellular Localization of Leukemia Drug Targets 320
Table 33: 4SC’s Included Leukemia Pipeline Composition and Competitive Fall-Out 327
Table 34: Abbott’s Included Leukemia Pipeline Composition and Competitive Fall-Out 328
Table 35: Abiogen’s Included Leukemia Pipeline Composition and Competitive Fall-Out 330
Table 36: Actinium Pharmaceuticals’ Included Leukemia Pipeline Composition and Competitive Fall-Out 331
Table 37: AEgera’s Included Leukemia Pipeline Composition and Competitive Fall-Out 332
Table 38: Aeterna Zentaris’ Included Leukemia Pipeline Composition and Competitive Fall-Out 334
Table 39: Agennix’s Included Leukemia Pipeline Composition and Competitive Fall-Out 336
Table 40: Alexion’s Included Leukemia Pipeline Composition and Competitive Fall-Out 337
Table 41: Alfa Wassermann’s Included Leukemia Pipeline Composition and Competitive Fall-Out 338
Table 42: Ambit Biosciences’ Included Leukemia Pipeline Composition and Competitive Fall-Out 340
Table 43: Amgen’s Included Leukemia Pipeline Composition and Competitive Fall-Out 342
Table 44: Antigenics’ Included Leukemia Pipeline Composition and Competitive Fall-Out 343
Table 45: Antisoma’s Included Leukemia Pipeline Composition and Competitive Fall-Out 345
Table 46: Ariad’s Included Leukemia Pipeline Composition and Competitive Fall-Out 347
Table 47: Arno Therapeutics’ Included Leukemia Pipeline Composition and Competitive Fall-Out 349
Table 48: Array BioPharma’s Included Leukemia Pipeline Composition and Competitive Fall-Out 350
Table 49: Asahi Kasei Pharma’s Included Leukemia Pipeline Composition and Competitive Fall-Out 351
Table 50: Ascenta Therapeutics’ Included Leukemia Pipeline Composition and Competitive Fall-Out 352
Table 51: Astellas’ Included Leukemia Pipeline Composition and Competitive Fall-Out 353
Table 52: Astex Therapeutics’ Included Leukemia Pipeline Composition and Competitive Fall-Out 354
Table 53: AstraZeneca’s Included Leukemia Pipeline Composition and Competitive Fall-Out 356
Table 54: Attenuon’s Included Leukemia Pipeline Composition and Competitive Fall-Out 357
Table 55: Bayer’s Included Leukemia Pipeline Composition and Competitive Fall-Out 358
Table 56: BioCryst Pharmaceuticals’ Included Leukemia Pipeline Composition and Competitive Fall-Out 360
Table 57: Biogen Idec’s Included Leukemia Pipeline Composition and Competitive Fall-Out 361
Table 58: Bioton’s Included Leukemia Pipeline Composition and Competitive Fall-Out 364
Table 59: Bioton’s Included Leukemia Pipeline Composition and Competitive Fall-Out 366
Table 60: Bristol-Myers Squibb’s Included Leukemia Pipeline Composition and Competitive Fall-Out 368
Table 61: BTG’s Included Leukemia Pipeline Composition and Competitive Fall-Out 370
Table 62: Calistoga Pharmaceuticals’ Included Leukemia Pipeline Composition and Competitive Fall-Out 372
Table 63: Callisto Pharmaceuticals’ Included Leukemia Pipeline Composition and Competitive Fall-Out 373
Table 64: Celator Pharmaceuticals’ Included Leukemia Pipeline Composition and Competitive Fall-Out 375
Table 65: Cell Genesys’ Included Leukemia Pipeline Composition and Competitive Fall-Out 376
Table 66: Cell Therapeutics’ Included Leukemia Pipeline Composition and Competitive Fall-Out 377
Table 67: Cephalon’s Included Leukemia Pipeline Composition and Competitive Fall-Out 379
Table 68: CJ Corp’s Included Leukemia Pipeline Composition and Competitive Fall-Out 380
Table 69: Clavis Pharma’s Included Leukemia Pipeline Composition and Competitive Fall-Out 382
Table 70: Curacyte’s Included Leukemia Pipeline Composition and Competitive Fall-Out 383
Table 71: Cyclacel’s Included Leukemia Pipeline Composition and Competitive Fall-Out 384
Table 72: Cylene Pharmaceuticals’ Included Leukemia Pipeline Composition and Competitive Fall-Out 385
Table 73: CytImmune Sciences’ Included Leukemia Pipeline Composition and Competitive Fall-Out 386
Table 74: Cytokinetics’ Included Leukemia Pipeline Composition and Competitive Fall-Out 387
Table 75: Daiichi Sankyo’s Included Leukemia Pipeline Composition and Competitive Fall-Out 388
Table 76: Dainippon Sumitomo Pharma’s Included Leukemia Pipeline Composition and Competitive Fall-Out 389
Table 77: Dara Biosciences’ Included Leukemia Pipeline Composition and Competitive Fall-Out 390
Table 78: Deciphera Pharmaceuticals’ Included Leukemia Pipeline Composition and Competitive Fall-Out 391
Table 79: Dong-A’s Included Leukemia Pipeline Composition and Competitive Fall-Out 393
Table 80: Eleos’ Included Leukemia Pipeline Composition and Competitive Fall-Out 395
Table 81: Eli Lilly’s Included Leukemia Pipeline Composition and Competitive Fall-Out 396
Table 82: Enzon’s Included Leukemia Pipeline Composition and Competitive Fall-Out 398
Table 83: EpiCept’s Included Leukemia Pipeline Composition and Competitive Fall-Out 400
Table 84: Exelixis’ Included Leukemia Pipeline Composition and Competitive Fall-Out 401
Table 85: ExonHit Therapeutics’ Included Leukemia Pipeline Composition and Competitive Fall-Out 403
Table 86: Gemin X Pharmaceuticals’ Included Leukemia Pipeline Composition and Competitive Fall-Out 404
Table 87: Genentech’s Included Leukemia Pipeline Composition and Competitive Fall-Out 405
Table 88: Genmab’s Included Leukemia Pipeline Composition and Competitive Fall-Out 408
Table 89: Genta’s Included Leukemia Pipeline Composition and Competitive Fall-Out 410
Table 90: Genzyme’s Included Leukemia Pipeline Composition and Competitive Fall-Out 412
Table 91: Geron’s Included Leukemia Pipeline Composition and Competitive Fall-Out 414
Table 92: GlaxoSmithKline’s Included Leukemia Pipeline Composition and Competitive Fall-Out 416
Table 93: Gloucester Pharmaceuticals’ Included Leukemia Pipeline Composition and Competitive Fall-Out 418
Table 94: GlycoGenesys’ Included Leukemia Pipeline Composition and Competitive Fall-Out 419
Table 95: Hayashibara’s Included Leukemia Pipeline Composition and Competitive Fall-Out 420
Table 96: Hoffmann-La Roche’s Included Leukemia Pipeline Composition and Competitive Fall-Out 422
Table 97: ImClone Systems’ Included Leukemia Pipeline Composition and Competitive Fall-Out 424
Table 98: Immunomedics’ Included Leukemia Pipeline Composition and Competitive Fall-Out 425
Table 99: Innate Pharma’s Included Leukemia Pipeline Composition and Competitive Fall-Out 427
Table 100: Innovive’s Included Leukemia Pipeline Composition and Competitive Fall-Out 428
Table 101: Isis Pharmaceuticals’ Included Leukemia Pipeline Composition and Competitive Fall-Out 429
Table 102: Italfarmaco’s Included Leukemia Pipeline Composition and Competitive Fall-Out 430
Table 103: Johnson & Johnson’s Included Leukemia Pipeline Composition and Competitive Fall-Out 431
Table 104: Kanisa’s Included Leukemia Pipeline Composition and Competitive Fall-Out 432
Table 105: Kyowa Hakko Kirin’s Included Leukemia Pipeline Composition and Competitive Fall-Out 433
Table 106: LG Life Sciences’ Included Leukemia Pipeline Composition and Competitive Fall-Out 434
Table 107: Lorus Therapeutics’ Included Leukemia Pipeline Composition and Competitive Fall-Out 437
Table 108: MAT Biopharma’s Included Leukemia Pipeline Composition and Competitive Fall-Out 438
Table 109: MaxCyte’s Included Leukemia Pipeline Composition and Competitive Fall-Out 439
Table 110: Meda’s Included Leukemia Pipeline Composition and Competitive Fall-Out 440
Table 111: Medarex’s Included Leukemia Pipeline Composition and Competitive Fall-Out 442
Table 112: MethylGene’s Included Leukemia Pipeline Composition and Competitive Fall-Out 444
Table 113: Micromet’s Included Leukemia Pipeline Composition and Competitive Fall-Out 445
Table 114: MorphoSys’ Included Leukemia Pipeline Composition and Competitive Fall-Out 447
Table 115: NanoMed Pharmaceuticals’ Included Leukemia Pipeline Composition and Competitive Fall-Out 448
Table 116: Nerviano Medical Sciences’ Included Leukemia Pipeline Composition and Competitive Fall-Out 449
Table 117: NIH’s Included Leukemia Pipeline Composition and Competitive Fall-Out 450
Table 118: Nippon Shinyaku’s Included Leukemia Pipeline Composition and Competitive Fall-Out 452
Table 119: Novartis’ Included Leukemia Pipeline Composition and Competitive Fall-Out 454
Table 120: Novogen’s Included Leukemia Pipeline Composition and Competitive Fall-Out 459
Table 121: PDL BioPharma’s Included Leukemia Pipeline Composition and Competitive Fall-Out 460
Table 122: Peplin’s Included Leukemia Pipeline Composition and Competitive Fall-Out 462
Table 123: Pfizer’s Included Leukemia Pipeline Composition and Competitive Fall-Out 463
Table 124: Pharmacyclics’ Included Leukemia Pipeline Composition and Competitive Fall-Out 466
Table 125: PharmaMar’s Included Leukemia Pipeline Composition and Competitive Fall-Out 467
Table 126: PIERIS Proteolab’s Included Leukemia Pipeline Composition and Competitive Fall-Out 468
Table 127: Rigel’s Included Leukemia Pipeline Composition and Competitive Fall-Out 469
Table 128: Sanofi-Aventis’ Included Leukemia Pipeline Composition and Competitive Fall-Out 470
Table 129: Santaris Pharma’s Included Leukemia Pipeline Composition and Competitive Fall-Out 471
Table 130: SBIO’s Included Leukemia Pipeline Composition and Competitive Fall-Out 472
Table 131: Schering-Plough’s Included Leukemia Pipeline Composition and Competitive Fall-Out 473
Table 132: SciGen’s Included Leukemia Pipeline Composition and Competitive Fall-Out 474
Table 133: Seattle Genetics’ Included Leukemia Pipeline Composition and Competitive Fall-Out 476
Table 134: Sepal Pharma’s Included Leukemia Pipeline Composition and Competitive Fall-Out 477
Table 135: Servier’s Included Leukemia Pipeline Composition and Competitive Fall-Out 478
Table 136: Shantha Biotechnics’ Included Leukemia Pipeline Composition and Competitive Fall-Out 480
Table 137: Sidus’ Included Leukemia Pipeline Composition and Competitive Fall-Out 482
Table 138: Spirogen’s Included Leukemia Pipeline Composition and Competitive Fall-Out 484
Table 139: Stemline Therapeutics’ Included Leukemia Pipeline Composition and Competitive Fall-Out 485
Table 140: SuperGen’s Included Leukemia Pipeline Composition and Competitive Fall-Out 486
Table 141: Supratek Pharma’s Included Leukemia Pipeline Composition and Competitive Fall-Out 488
Table 142: Swedish Orphan’s Included Leukemia Pipeline Composition and Competitive Fall-Out 490
Table 143: SymBio Pharmaceuticals’ Included Leukemia Pipeline Composition and Competitive Fall-Out 492
Table 144: Takeda’s Included Leukemia Pipeline Composition and Competitive Fall-Out 493
Table 145: Teva’s Included Leukemia Pipeline Composition and Competitive Fall-Out 495
Table 146: TopoTarget’s Included Leukemia Pipeline Composition and Competitive Fall-Out 496
Table 147: Trion Pharma’s Included Leukemia Pipeline Composition and Competitive Fall-Out 498
Table 148: Trubion’s Included Leukemia Pipeline Composition and Competitive Fall-Out 499
Table 149: Vertex Pharmaceuticals’ Included Leukemia Pipeline Composition and Competitive Fall-Out 500
Table 150: Vion Pharmaceuticals’ Included Leukemia Pipeline Composition and Competitive Fall-Out 501
Table 151: VioQuest’s Included Leukemia Pipeline Composition and Competitive Fall-Out 503
Table 152: Wyeth’s Included Leukemia Pipeline Composition and Competitive Fall-Out 505
Table 153: Yamasa Corporation’s Included Leukemia Pipeline Composition and Competitive Fall-Out 507
Table 154: Zenyaku Kogyo’s Included Leukemia Pipeline Composition and Competitive Fall-Out 509
Table 155: ZymoGenetics’ Included Leukemia Pipeline Composition and Competitive Fall-Out 511
Table 156: Non-industrial Sources’ Included Leukemia Pipeline Composition and Competitive Fall-Out 512

This report includes 126 investigators:
4SC
Abbott
Abiogen
Actinium Pharmaceuticals
AEgera
Aeterna Zentaris
Agennix
Alexion
Alfa Wassermann
Ambit Biosciences
Amgen
Antigenics
Antisoma
Ariad
Arno Therapeutics
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Bayer
BioCryst Pharmaceuticals
Biogen Idec
Bioton
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calistoga Pharmaceuticals
Callisto Pharmaceuticals
Celator Pharmaceuticals
Cell Genesys
Cell Therapeutics
Cephalon
CJ Corp
Clavis Pharma
Curacyte
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dong-A
Eleos
Eli Lilly
Enzon
EpiCept
Exelixis
ExonHit Therapeutics
Gemin X Pharmaceuticals
Genentech
Genmab
Genta
Genzyme
Geron
GlaxoSmithKline
Gloucester Pharmaceuticals
GlycoGenesys
Hayashibara
Hoffmann-La Roche
ImClone Systems
Immunomedics
Innate Pharma
Innovive
Isis Pharmaceuticals
Italfarmaco
Johnson & Johnson
Kanisa
Kyowa Hakko Kirin
LG Life Sciences
Lorus Therapeutics
MAT Biopharma
MaxCyte
Meda
Medarex
MethylGene
Micromet
MorphoSys
NanoMed Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Shinyaku
Non-industrial source
Novartis
Novogen
PDL BioPharma
Peplin
Pfizer
Pharmacyclics
PharmaMar
PIERIS Proteolab
Rigel
Sanofi-Aventis
Santaris Pharma
SBIO
Schering-Plough
SciGen
Seattle Genetics
Sepal Pharma
Servier
Shantha Biotechnics
Sidus
Spirogen
Stemline Therapeutics
SuperGen
Supratek Pharma
Swedish Orphan
SymBio Pharmaceuticals
Takeda
Teva
TopoTarget
Trion Pharma
Trubion
Vertex Pharmaceuticals
Vion Pharmaceuticals
VioQuest
Wyeth
Yamasa Corporation
Zenyaku Kogyo
ZymoGenetics
This report includes 175 leukemia drugs. From Ceased to Marketed.
A shortlist of drugs included are:
alemtuzumab
alvocidib
amonafide malate
amsacrine
bosutinib
clofarabine
cloretazine
CSF-GM
cytarabine
cytarabine ocfosfate
dasatinib
decitabine
enocitabine
gemtuzumab ozogamicin
histamine dihydrochloride
idarubicin
imatinib mesilate
interferon
lestaurtinib
leukaemia vaccine
lumiliximab
midostaurin
mitoxantrone
nilotinib
oblimersen sodium
ofatumumab
peginterferon alfa-2b
pentostatin
razoxane
rituximab
sobuzoxane
tamibarotene
teniposide
tipifarnib

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking.
    To find out more about Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
This report is written for you to identify your competition and understand which targeting strategies are at work within anti-angiogenic drug development in oncology. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversly it may reveal unexpected competition for you. Learn More


Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?
This report comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. The report extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target profiles, and assesses them in 69 different cancer indications. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Leukemia, Angiogenesis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Learn More


Triple Analysis: Leukemia, Lymphoma and Melanoma
This triple analysis focuses on cancer drug development strategies in Leukemia, Lymphoma and Melanoma. Learn More